AAM Urges Action On Product Hopping And Patent Thickets
The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.
You may also be interested in...
Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.
Patient-oriented educational materials on biosimilars published by the US Food and Drug Administration have been welcomed by the local off-patent industry.
A recent study by the AAM’s Biosimilars Council has found that delayed access to biosimilars has cost the US healthcare system $7.6bn since 2015; meanwhile, Medicare has foregone more than $1.2bn in savings from biosimilars since 2015.